t(6;9)(MYB‐NFIB) in head and neck adenoid cystic carcinoma: A systematic review with meta‐analysis

Almeida-Pinto, Yasmin Dias de; Costa, Sara Ferreira dos Santos; Andrade, Bruno Augusto Benevenuto de; Altemani, Albina; Vargas, Pablo Agustı́n; Abreu, Lucas Guimarães; Fonseca, Felipe Paiva

doi:10.1111/odi.12984

Cited by 38 publications

(30 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A MYB oncogene fusion, through Akt and mitogenactivated protein kinase (MAPK) signaling pathways, activates the expression of NSR, MET, EGFR, IGF1R, and specifically IGF2. The latter, by autocrine stimulation, controls the expression of MYB-NFIB in ACC cells, increasing proliferation and generating changes in the cell cycle and RNA processing (89)(90)(91). Other MYB-related fusions were described, but at lower frequencies than MYB-NFIB.…”

Section: Myb-nfib Pathwaymentioning

confidence: 99%

Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease

et al. 2020

View full text Add to dashboard Cite

Salivary gland carcinomas (SGCs) account for <5% of head and neck malignant neoplasms, further subcategorized in over 20 histological subtypes. For the most part, treatment for advanced disease is guided by morphology. SGCs in general respond poorly to a wide array of standard chemotherapy, with short durability, and significant toxicity. More recently, next-generation sequencing provided significant input on the molecular characterization of each SGC subtype, not only improving diagnostic differentiation between morphologically similar tumor types but also identifying novel driver pathways that determine tumor biology and may be amenable to targeted therapy. Among the most common histological subtype is adenoid cystic carcinoma, which often harbors a chromosome translocation resulting in an MYB-NFIB oncogene, with various degrees of Myb surface expression. In a smaller subset, NOTCH1 mutations occur, conferring a more aggressive pattern and potential sensitivity to Notch inhibitors. Salivary duct carcinomas may overexpress Her-2 and androgen receptors, with promising clinical outcomes after exposure to targeted therapies approved for other indications. Secretory carcinoma, previously known as mammary analog secretory carcinoma, is distinguished by an ETV6-NTRK3 fusion that can both help differentiate it from its morphologically similar acinar cell carcinoma and make it susceptible to Trk inhibitors. In the present article, we discuss the molecular abnormalities, their impact on tumor biology, and therapeutic opportunities for the most common SGC subtypes and review published and ongoing clinical trials and future perspectives for this rare disease.

show abstract

Section: Myb-nfib Pathwaymentioning

confidence: 99%

Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…This report indicates that molecular interactions between MYB and RUNX1 pathways may influence the clinical behaviour of ACC. However, further studies are suggested to determine the possible correlation between these key genes in ACC pathogenesis and to determine the possible association between RUNX1 expression and MYB‐NFIB translocation, an important molecular event frequently present in ACC (de Almeida‐Pinto et al., 2019).…”

Section: Discussionmentioning

confidence: 99%

Prognostic importance of RUNX1 expression for head and neck adenoid cystic carcinoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Objective In the present study, we aimed to investigate the prognostic value of RUNX1 expression in 76 patients with adenoid cystic carcinoma (ACC). Materials and Methods All cases were arranged in tissue microarray blocks and submitted to immunohistochemistry against RUNX1. These results were statistically correlated with clinicopathologic features, including age, gender, tumour site, tumour size, lymph node status, AJCC clinical stage, distant metastasis, treatment, recurrences, follow‐up, histologic pattern, vascular and neural invasion, all of which obtained from patient's medical records. Results RUNX1 was expressed in the nuclei of tumour cells, with a mean of 18.1% of positivity. Nuclear RUNX1 expression was significantly associated with AJCC clinical stage (p < .0001), solid histologic pattern (p < .0001), vascular invasion (p < .0001) and presence of local recurrence (p < .0001). Using univariate and multivariate analyses, RUNX1 nuclear expression was significantly associated with a lower disease‐free survival (p < .0001 and p = .028, respectively) and disease‐specific survival (p < .0001 and p = .018, respectively) rates. Conclusion In summary, RUNX1 nuclear expression may represent an indicator of unfavourable outcome for patients affected by head and neck ACC.

show abstract

“…Mucoepidermoid carcinoma is the most common malignant salivary gland tumor in children and adults (1). Most mucoepidermoid carcinoma identified in the head and neck can also occur in other sites, such as lung, skin, breast, liver, and so forth (1)(2)(3). Pulmonary mucoepidermoid carcinoma (PMEC) is rare, which originates from the submucosal glands of the tracheobronchial tree (4,5).…”

Section: Introductionmentioning

confidence: 99%

Nomogram for predicting the survival rate of primary pulmonary mucoepidermoid carcinoma patients: a retrospective study based on SEER database

Lin¹,

Liang²,

Wang³

et al. 2021

Ann Transl Med

View full text Add to dashboard Cite

Background: Primary pulmonary mucoepidermoid carcinoma (PMEC) is a rare malignant tumor, and the clinical manifestations lack specificity. The study evaluates the prognostic factors and constructs a practicable nomogram to estimate the individualized survival status for PMEC patients.Methods: Surveillance, Epidemiology, and End Results (SEER) database was used to selected eligible patients between 1975 and 2016. The baseline characteristics including age, sex, race, marital status, tumor stage, differentiated degree, tumor laterality, primary tumor site, tumor size, lymph node metastases status, distant metastases status, surgery, chemotherapy, and radiation. We identified independent variables to build 3-, 5-, 10-year overall survival (OS) and cancer-specific survival (CSS) nomograms by univariate and multivariate analyses.Results: A total of 438 PMEC patients met our selection criteria. In multivariate analysis, age, tumor stage, differentiated grade, tumor size, lymph node metastases status, distant metastases status, surgery and radiation were involved in the nomogram. The C-index (0.887 (95% CI: 0.863-0.911), calibrate plots and ROC curves (AUC =0.941, 0.951, 0.935 for 3-, 5-, 10-year OS, respectively) indicated the satisfied accuracy and practicability of our nomograms. Compared to TNM system, our model also showed a superior prediction (IDI =0.167, 0.171, 0.172, P<0.001). Conclusions:We built OS (CSS) nomograms that can accurately estimate individualized survival time and identify the risk classification of PMEC.

show abstract

t(6;9)(MYB‐NFIB) in head and neck adenoid cystic carcinoma: A systematic review with meta‐analysis

Cited by 38 publications

References 23 publications

Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease

Salivary Gland Carcinoma: Novel Targets to Overcome Treatment Resistance in Advanced Disease

Prognostic importance of RUNX1 expression for head and neck adenoid cystic carcinoma

Nomogram for predicting the survival rate of primary pulmonary mucoepidermoid carcinoma patients: a retrospective study based on SEER database

Contact Info

Product

Resources

About